Literature DB >> 34050501

The Symptoms and Clinical Manifestations Observed in COVID-19 Patients/Long COVID-19 Symptoms that Parallel Toxoplasma gondii Infections.

Kevin Roe1.   

Abstract

Entities:  

Keywords:  Brain Infections; Latent Infections; Protozoa; Protozoan Infections; SARS-CoV-2 Mortality

Mesh:

Year:  2021        PMID: 34050501      PMCID: PMC8163588          DOI: 10.1007/s11481-021-09997-0

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


× No keyword cloud information.
Several peculiar symptoms and subpopulation mortality rates have been documented in COVID-19 patients and in patients manifesting the post-infection symptoms now called Long COVID-19 (Carvalho-Schneider et al. 2020; Yelin et al. 2020; Mendelson et al. 2020; Nemani et al. 2021; Kozloff et al. 2020; Zheng et al. 2020a, b). As an example, in a study of 293 reverse transcriptase-PCR test confirmed COVID-19 hospital inpatients and outpatients in Tours, France, even after excluding 64 critical disease ICU patients and 36 residents transferred to a nursing home or long-term care facility, there were still 19 deaths (Carvalho-Schneider et al. 2020). In a follow-up study of 130 recovered non-critical COVID-19 patients at the same hospital, over 22% of the patients on day 60 after symptom onset reported the unusual symptoms of anosmia (impaired smell) and ageusia (impaired taste), and over 7% still reported the symptoms of dyspnoea (shortness of breath) (Carvalho-Schneider et al. (2020). Over 33% of these recovered COVID-19 patients reported that they felt as bad on day 60 after symptom onset as they felt during their acute disease phase (Carvalho-Schneider et al. 2020). One explanatory hypothesis would be that for some individuals these peculiar symptoms and subpopulation mortality rates are the consequence of SARS-CoV-2 virus infections working in bidirectional synergy with one or more existing latent pathogen infections, by means of induced mutually beneficial immune cell dysfunctions, including T cell exhaustion (Zheng et al. 2020a, b; Varikuti et al. 2018; Xiao et al. 2018). Based on medical observations, the most plausible participating latent pathogen infection is the wide-spread protozoan parasite Toxoplasma gondii (Varikuti et al. 2018; Xiao et al. 2018). Protozoan parasites, including Toxoplasma gondii, cause intracellular infections in a large percentage of the global human population (Varikuti et al. 2018; Xiao et al. 2018). T. gondii has three life cycles, including tachyzoites that cause acute infection, bradyzoite tissue cysts that maintain a latent infection, and sporozoites that infect new hosts by food or water (Xiao et al. 2018). Other than by occasional T. gondii transmissions by organ or tissue transplant procedures, a new host is usually infected after ingestion of sporozoites allowing activated protozoa to penetrate the gut epithelium and reach the host's bloodstream (Xiao et al. 2018). Protozoan parasites, including T. gondii, can latently infect the brain and central nervous system (CNS), leaving tissue cysts in hosts and immune system dysfunctions (Xiao et al. 2018). T. gondii has been extensively linked to numerous mental illnesses, including recent onset psychiatric illnesses, such as schizophrenia, in some individuals (Xiao et al. 2018). T. gondii bradyzoites have been detected in muscles, brain neurons, and the CNS including the retina of the eye (Xiao et al. 2018). Humans with brain infections by T. gondii present a neuroinflammation of the brain, activated microglia and astrocytes in the brain, and complement factor C1q near the cysts (Xiao et al. 2018). Furthermore, it has been shown that T. gondii cysts in the brain induce major disruptions in the levels of glutamate, gamma-aminobutyric acid, dopamine and other neurotransmitters (Xiao et al. 2018). It has been asserted that such neurotransmitter disruptions also induce schizophrenia, particularly in cases of recent onset of schizophrenia (Xiao et al. 2018). In fact, a statistically significant link between schizophrenia and a higher mortality rate from SARS-CoV-2 has been reported, with a mortality odds ratio of 2.67 compared to reference patients (Nemani et al. 2021). This could result from even a small percentage of such patients having schizophrenia caused by T. gondii cysts . Infected hosts have also demonstrated CD8 T cell exhaustion, which is believed to ultimately induce T. gondii reactivations and localized inflammations (Xiao et al. 2018). It is particularly noteworthy that T cell exhaustion, such as CD8 T cell exhaustion, and a reduced host antiviral response have also been seen in COVID-19 patients who exhibit worse infections and worse outcomes (Zheng et al. 2020a, b).

An Explanation for Higher COVID-19 Mortality in Other Categories

COVID-19 has several distinctive and peculiar hospitalization and mortality characteristics (Gottlieb et al. 2020; Harrison et al. 2020; Hamer et al. 2020). In a large studies of 31,461 adults in the U.S., and 334,329 patients in the U.K., COVID-19 patients had increasing hospitalization rates for increasingly older adults (adjusted odds ratios of .92 for 0-18 year age group, 1.0 for 19-44, 1.67 for 45-54, 1.99 for 55-64, 4.55 for 65-74, and 7.32 for adults over 75), a progressively higher mortality rate for older adults (adjusted odds ratio ranging from 1.06 to 1.08 per extra year of age), a higher mortality rate of males compared to females (adjusted odds ratio ranging from 1.6 to 1.75 compared to females), and a higher mortality rate for patients reaching body mass indexes of 30 to 35 (adjusted odds ratio ranging from 1.2 to 1.37) (Gottlieb et al. 2020; Harrison et al. 2020; Hamer et al. 2020). There are significant observational similarities between the mortality rates of the preceding categories and their latent pathogen infection rates with protozoan parasites like T. gondii (Harrison et al. 2020; Hamer et al. 2020; Wilking et al. 2016). In Germany in 2016, the seroprevalence of IgG antibodies to T. gondii in 6,663 adults ranging in age 18 to 79 progressively increased from 20% in the 18 to 29 age group to 77% in the 70 to 79 age group, where males had higher infection rates than females (an odds ratio of 1.8 for males), and higher infection rates for adults with body mass indexes over 30 (with an odds ratio of 1.3) (Wilking et al. 2016). If T. gondii infection rates are approximately equivalent among relatively high income countries (e.g., the U.S., the U.K. and Germany), the close matches between increased COVID-19 mortality rates and T. gondii infection rates in the same corresponding subpopulations could be logically explained by the involvement of a mutually beneficial immune system dysfunction, such as CD8 T cell exhaustion, assisting both COVID-19 and T. gondii infections. This synergy could explain a large number of the peculiar aspects of COVID-19. But this synergy could also explain many aspects of Long COVID-19.

An Explanation for Long COVID-19

Latent infections, including T. gondii infections, can explain the increased mortality rates for several categories of COVID-19 patients. Such latent infections can also explain why several patients suffer severe COVID-19 symptoms, and explain why several patients suffer "Long COVID-19" (Carvalho-Schneider et al. 2020; Yelin et al. 2020; Mendelson et al. 2020). A large fraction of patients, after their COVID-19 viral infections, suffer several neurological and psychological symptoms of Long COVID-19 for several months, including: fatigue, dyspnoea (labored breathing/shortness of breath), anosmia (impaired sense of smell), dysgeusia (impaired sense of taste), chest pain, joint pain, hair loss, memory and attention deficits, anxiety, depression, and sleep disorders, (Carvalho-Schneider et al. 2020; Yelin et al. 2020; Mendelson et al. 2020). It is significant that virtually all of the diverse and distinctive symptoms of Long COVID-19 can be explained as symptoms of toxoplasmosis in patients having activated or reactivated T. gondii (Vidal 2019). Toxoplasmosis patients suffer a wide variety of symptoms, including dyspnoea, fevers, seizures, headaches, changes in vision, altered mental status, focal neurological deficits, mental confusion, cognitive dysfunction, ataxia, behavioral or psychomotor changes, involuntary movements, pneumonia, and a spectrum of cranial nerve palsies (Vidal 2019). Several distinctive Long COVID-19 symptoms can be matched if toxoplasmosis induced cranial nerve palsies affect the functions of the 12 cranial nerves, creating symptoms including anosmia from a palsy of the olfactory nerve (I), vertigo (dizziness), tinnitus and otalgia (earache) from a palsy of the vestibulocochlear nerve (VIII), and dysgeusia from palsies of the facial nerve (VII), glossopharyngeal nerve (IX), and vagus nerve (X) (Khaku et al. 2017). Table 1 lists the symptoms of toxoplasmosis versus the symptoms of COVID-19 and/or Long COVID-19. Toxoplasmosis symptoms can match several symptoms exhibited in COVID-19 and/or Long COVID-19 patients.
Table 1

The Symptoms of Toxoplasmosis Versus the Symptoms of COVID-19 and/or Long COVID-19—References (Carvalho-Schneider et al. 2020; Yelin et al. 2020; Mendelson et al. 2020; Wilking et al. 2016; Vidal 2019; Khaku et al. 2017)

SymptomToxoplasmosisCOVID-19Comment
FatigueDocumentedDocumentedDefinitely seen in both
Dyspnoea/Labored breathingDocumentedDocumentedDefinitely seen in both
FeverDocumentedDocumentedDefinitely seen in both
Altered Mental StatusaDocumentedDocumentedDefinitely seen in both
Mental ConfusionaDocumentedDocumentedDefinitely seen in both
Cognitive DysfunctionaDocumentedDocumentedDefinitely seen in both
Behavioral ChangesaDocumentedDocumentedDefinitely seen in both
Neurological DeficitsDocumentedDocumentedDefinitely seen in both
Ataxia/Incoordination*DocumentedDocumentedDefinitely seen in both
Involuntary Movements*DocumentedDocumentedDefinitely seen in both
Anosmia/Impaired smellPossibleDocumentedT. gondii C.N. palsy induced
Dysgeusia/Impaired tastePossibleDocumentedT. gondii C.N. palsy induced
Chest PainPossibleDocumentedT. gondii nerve palsy induced
Arthralgia/Joint painPossibleDocumentedT. gondii nerve palsy induced
Myalgia/Muscle painPossibleDocumentedT. gondii nerve palsy induced
Hair LossPossibleDocumentedResultant stress could do this
AnxietyPossibleDocumentedResultant stress could do this
DepressionPossibleDocumentedResultant stress could do this
SeizuresDocumentedPossibleSeen in COVID-19
HeadachesDocumentedPossibleSeen in COVID-19
Vision ChangesDocumentedPossibleSeen in COVID-19
PneumoniaDocumentedDocumentedSeen in COVID-19

C. N. palsy means cranial nerve palsy

*Ataxia (Incoordination or lack of coordination) and Involuntary Movements are broad symptoms and may be documented with overlaps

aAltered Mental Status, Mental Confusion, Cognitive Dysfunction, and Behavioral Changes are broad symptoms and may be documented with overlaps

The Symptoms of Toxoplasmosis Versus the Symptoms of COVID-19 and/or Long COVID-19—References (Carvalho-Schneider et al. 2020; Yelin et al. 2020; Mendelson et al. 2020; Wilking et al. 2016; Vidal 2019; Khaku et al. 2017) C. N. palsy means cranial nerve palsy *Ataxia (Incoordination or lack of coordination) and Involuntary Movements are broad symptoms and may be documented with overlaps aAltered Mental Status, Mental Confusion, Cognitive Dysfunction, and Behavioral Changes are broad symptoms and may be documented with overlaps In summary, protozoan parasite brain infections by T. gondii have been observed to cause neuroinflammations, neurotransmitter disruptions, and immune dysfunctions, such as CD8 T cell exhaustion. Such infections have been linked to some cases of schizophrenia. Observations of an increased SARS-CoV-2 mortality in schizophrenia patients can be explained by some schizophrenia patients exhibiting T. gondii brain infections that induce neuroinflammation and T cell exhaustion, such as CD8 T cell exhaustion, that assist the SARS-CoV-2 virus. Furthermore, the very close matches between COVID-19 mortality rates and T. gondii infection rates in several of the same corresponding subpopulation categories imply that latent T. gondii infections can explain several unusual mortality aspects of COVID-19. Finally, the partial or full reactivation of latent T. gondii infections can explain why many individuals exhibit a very diverse set of symptoms of Long COVID-19 well after the end of their SARS-CoV-2 infections.
  15 in total

1.  Long-COVID: An evolving problem with an extensive impact.

Authors:  M Mendelson; J Nel; L Blumberg; S A Madhi; M Dryden; W Stevens; F W D Venter
Journal:  S Afr Med J       Date:  2020-11-23

Review 2.  Guidelines for radiographic imaging of cranial neuropathies.

Authors:  Aliasgher Khaku; Vijay Patel; Thomas Zacharia; David Goldenberg; Johnathan McGinn
Journal:  Ear Nose Throat J       Date:  2017 Oct-Nov       Impact factor: 1.697

3.  Association of Psychiatric Disorders With Mortality Among Patients With COVID-19.

Authors:  Katlyn Nemani; Chenxiang Li; Mark Olfson; Esther M Blessing; Narges Razavian; Ji Chen; Eva Petkova; Donald C Goff
Journal:  JAMA Psychiatry       Date:  2021-04-01       Impact factor: 21.596

Review 4.  Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites.

Authors:  Sanjay Varikuti; Bijay Kumar Jha; Greta Volpedo; Nathan M Ryan; Gregory Halsey; Omar M Hamza; Bradford S McGwire; Abhay R Satoskar
Journal:  Front Microbiol       Date:  2018-11-30       Impact factor: 5.640

5.  The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders.

Authors:  Nicole Kozloff; Benoit H Mulsant; Vicky Stergiopoulos; Aristotle N Voineskos
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

6.  Follow-up of adults with noncritical COVID-19 two months after symptom onset.

Authors:  Claudia Carvalho-Schneider; Emeline Laurent; Adrien Lemaignen; Emilie Beaufils; Céline Bourbao-Tournois; Saïd Laribi; Thomas Flament; Nicole Ferreira-Maldent; Franck Bruyère; Karl Stefic; Catherine Gaudy-Graffin; Leslie Grammatico-Guillon; Louis Bernard
Journal:  Clin Microbiol Infect       Date:  2020-10-05       Impact factor: 8.067

7.  Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study.

Authors:  Hendrik Wilking; Michael Thamm; Klaus Stark; Toni Aebischer; Frank Seeber
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

8.  Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis.

Authors:  Stephanie L Harrison; Elnara Fazio-Eynullayeva; Deirdre A Lane; Paula Underhill; Gregory Y H Lip
Journal:  PLoS Med       Date:  2020-09-10       Impact factor: 11.069

9.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients.

Authors:  Meijuan Zheng; Yong Gao; Gang Wang; Guobin Song; Siyu Liu; Dandan Sun; Yuanhong Xu; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

10.  Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom.

Authors:  Mark Hamer; Catharine R Gale; Mika Kivimäki; G David Batty
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-11       Impact factor: 11.205

View more
  5 in total

Review 1.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

2.  SARS-CoV-2 and Toxoplasma gondii shared symptoms suggest muscle cells and neurons are their chronic infection reservoirs.

Authors:  Kevin Roe
Journal:  Hum Cell       Date:  2022-10-10       Impact factor: 4.374

Review 3.  A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several categories of COVID-19 patients.

Authors:  Kevin Roe
Journal:  J Neurosci Res       Date:  2021-07-19       Impact factor: 4.433

4.  Is COVID-19 associated with latent toxoplasmosis?

Authors:  Salman Ghaffari; Narges Kalantari; Tahmineh Gorgani-Firouzjaee; Masomeh Bayani; Farzaneh Jalali; Meysam Aghajani Daroonkola
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-25       Impact factor: 4.223

5.  Plasma cell-free RNA characteristics in COVID-19 patients.

Authors:  Yanqun Wang; Jie Li; Lu Zhang; Hai-Xi Sun; Zhaoyong Zhang; Jinjin Xu; Yonghao Xu; Yu Lin; Airu Zhu; Yuxue Luo; Haibo Zhou; Yan Wu; Shanwen Lin; Yuzhe Sun; Fei Xiao; Ruiying Chen; Liyan Wen; Wei Chen; Fang Li; Rijing Ou; Yanjun Zhang; Tingyou Kuo; Yuming Li; Lingguo Li; Jing Sun; Kun Sun; Zhen Zhuang; Haorong Lu; Zhao Chen; Guoqiang Mai; Jianfen Zhuo; Puyi Qian; Jiayu Chen; Huanming Yang; Jian Wang; Xun Xu; Nanshan Zhong; Jingxian Zhao; Junhua Li; Jincun Zhao; Xin Jin
Journal:  Genome Res       Date:  2022-01-21       Impact factor: 9.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.